Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Morepen Laboratories approves hiving off of medical devices business
Subscribe To Our Newsletter & Stay Updated